New treatment targeting tau protein for Alzheimer's disease

Who could benefit from this research

What this research studies

This research focuses on developing an immunotherapy that targets acetylated tau protein, which is a key factor in the progression of Alzheimer's disease. The approach involves creating monoclonal antibodies that can bind to this modified tau protein, potentially reducing its harmful effects in the brain. By using mouse models, the researchers have shown promising results in protecting brain regions affected by Alzheimer's, such as the hippocampus. The goal is to translate these findings into a treatment that could improve the lives of patients suffering from Alzheimer's disease.

Why it matters

Where this research is happening

• Aeton Therapeutics, INC.
  Burlingame, United States Active

Researchers

• Principal investigator: Sinha, Anjana — Aeton Therapeutics, INC.
• Study coordinator: Sinha, Anjana

Related research

Other NIH-funded projects on the same topics.

• Immune cell aging and metabolism as a target for Alzheimer's treatment

  This work looks at whether aging immune cells called T cells and their fat-related metabolism drive Alzheimer's and whether changing them could point to new treatments for people with AD.

  NIH research Washington University · Saint Louis, United States · NIH-11336890

• Blood–brain barrier and tiny brain changes linked to side effects and outcomes of anti‑amyloid treatment for Alzheimer’s

  This project will look at blood–brain barrier health and small brain changes to help predict side effects and treatment outcomes for people with Alzheimer’s disease.

  NIH research University of California, San Diego · La Jolla, United States · NIH-11248850

• Understanding how aging immune cells contribute to Alzheimer's disease

  This study is looking at how aging immune cells called T cells might affect the buildup of harmful proteins in Alzheimer's disease, with the hope of finding new ways to help people with this condition.

  NIH research Washington University · Saint Louis, United States · NIH-11080924

• Investigating brain changes and risks from new Alzheimer's treatments

  This study is looking at how new treatments for Alzheimer's disease might affect the brain, especially any potential risks, so we can better understand how to keep patients safe while using these therapies.

  NIH research University of California, San Diego · La Jolla, United States · NIH-11052353

• Investigating immune interactions in Alzheimer's disease and testing a new immunotherapy

  This study is looking at how inflammation might impact Alzheimer's disease by checking certain markers in your blood and spinal fluid, and it will also test a new low-dose treatment to see if it helps improve brain function and memory over 22 weeks for people with Alzheimer's.

  NIH research Methodist Hospital Research Institute · Houston, United States · NIH-11004684

• Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model

  Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.

  NIH research Nathan S. Kline Institute for Psych Res · Orangeburg, United States · NIH-11627965

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.